Liza-Marie Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5805542/publications.pdf

Version: 2024-02-01

72 880 Example 2 30442 The papers citations is a significant paper of the paper of

18 27
h-index g-index

74 74 all docs docs citations

74 times ranked 993 citing authors

#	Article	IF	Citations
1	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	7.7	88
2	Pediatric Palliative Sedation Therapy with Propofol: Recommendations Based on Experience in Children with Terminal Cancer. Journal of Palliative Medicine, 2012, 15, 1082-1090.	0.6	58
3	Integrating nextâ€generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics. Cancer, 2017, 123, 2352-2359.	2.0	58
4	Ethics Consultation in Pediatrics: Long-Term Experience From a Pediatric Oncology Center. American Journal of Bioethics, 2015, 15, 3-17.	0.5	57
5	Illness and endâ€ofâ€ife experiences of children with cancer who receive palliative care. Pediatric Blood and Cancer, 2018, 65, e26895.	0.8	53
6	Predictors of Late Palliative Care Referral in Children With Cancer. Journal of Pain and Symptom Management, 2018, 55, 1550-1556.	0.6	36
7	Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 741-748.	2.3	35
8	Practical communication guidance to improve phase 1 informed consent conversations and decisionâ€making in pediatric oncology. Cancer, 2015, 121, 2439-2448.	2.0	34
9	Does phase 1 trial enrollment preclude quality endâ€ofâ€life care? Phase 1 trial enrollment and endâ€ofâ€life care characteristics in children with cancer. Cancer, 2015, 121, 1508-1512.	2.0	34
10	End-of-Life Care for Hospitalized Children. Pediatric Clinics of North America, 2014, 61, 835-854.	0.9	32
11	Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2â€visit consent model. Cancer, 2019, 125, 2455-2464.	2.0	29
12	Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancer. JAMA Pediatrics, 2019, 173, 477.	3.3	28
13	Are we meeting the informational needs of cancer patients and families? Perception of physician communication in pediatric oncology. Cancer, 2019, 125, 1518-1526.	2.0	28
14	Predictors of Location of Death for Children with Cancer Enrolled on a Palliative Care Service. Oncologist, 2018, 23, 1525-1532.	1.9	27
15	Impact of Race and Ethnicity on End-of-Life Experiences for Children With Cancer. American Journal of Hospice and Palliative Medicine, 2019, 36, 767-774.	0.8	26
16	Ethical considerations surrounding germline next-generation sequencing of children with cancer. Expert Review of Molecular Diagnostics, 2017, 17, 523-534.	1.5	23
17	Ethical issues in the care of adolescent and young adult oncology patients. Pediatric Blood and Cancer, 2019, 66, e27608.	0.8	22
18	Palliative Sedation With Propofol for an Adolescent With a DNR Order. Pediatrics, 2017, 140, .	1.0	20

#	Article	IF	Citations
19	Factors Associated With Declining to Participate in a Pediatric Oncology Next-Generation Sequencing Study. JCO Precision Oncology, 2020, 4, 202-211.	1.5	15
20	Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature. Journal of Adolescent and Young Adult Oncology, 2014, 3, 160-175.	0.7	13
21	The role of the pediatric anesthesiologist in relieving suffering at the end of life: when is palliative sedation appropriate in pediatrics?. Paediatric Anaesthesia, 2017, 27, 443-444.	0.6	11
22	The bereavement experience of adolescents and early young adults with cancer: Peer and parental loss due to death is associated with increased risk of adverse psychological outcomes. PLoS ONE, 2017, 12, e0181024.	1.1	11
23	Knowledge Is Power: Benefits, Risks, Hopes, and Decision-Making Reported by Parents Consenting to Next-Generation Sequencing for Children and Adolescents with Cancer. Seminars in Oncology Nursing, 2021, 37, 151167.	0.7	11
24	Recruiting Children for Clinical Trials: Lessons From Pediatric Oncology. American Journal of Bioethics, 2015, 15, 24-26.	0.5	9
25	Should Poor Social Support Be an Exclusion Criterion in Bone Marrow Transplantation?. American Journal of Bioethics, 2019, 19, 39-41.	0.5	8
26	Ethical Decision Making About End-of-life Care Issues by Pediatric Oncologists in Economically Diverse Settings. Journal of Pediatric Hematology/Oncology, 2015, 37, 257-263.	0.3	7
27	Managing Pandora's Box: Familial Expectations around the Return of (Future) Germline Results. AJOB Empirical Bioethics, 2022, 13, 152-165.	0.8	7
28	Beyond Parenting: The Responsibility of Multidisciplinary Health Care Providers in Early Intervention Policy Guidance. American Journal of Bioethics, 2018, 18, 58-60.	0.5	6
29	An Unusual Case of Ogilvie Syndrome in a Pediatric Oncology Patient Receiving Palliative Care after Failed Treatment with Neostigmine. Journal of Palliative Medicine, 2012, 15, 1042-1046.	0.6	5
30	Mitigating Challenges in Dual-Role Consent: Honoring Patient Preferences to Discuss Research Participation With Someone They Know. American Journal of Bioethics, 2019, 19, 30-32.	0.5	5
31	Outcomes and Disposition of Oncology Patients With Non-neutropenic Fever and Positive Blood Cultures. Journal of Pediatric Hematology/Oncology, 2021, 43, 47-51.	0.3	5
32	Clinically Significant? Depends on Whom You Ask. American Journal of Bioethics, 2012, 12, 18-20.	0.5	4
33	A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research and Human Subjects Research. American Journal of Bioethics, 2018, 18, 58-59.	0.5	4
34	A Pragmatic Trial of Suicide Risk Assessment and Ambulance Transport Decision Making Among Emergency Medical Services Providers: Implications for Patient Consent. American Journal of Bioethics, 2019, 19, 97-98.	0.5	4
35	A Cluster Randomized Trial to Screen for Abusive Head Trauma in the Pediatric Intensive Care Unit—How to Manage Site-Specific Evidence of Racial/Ethnic Disparity. American Journal of Bioethics, 2019, 19, 108-109.	0.5	4
36	Conflicts of Interest and Recommendations for Clinical Treatments That Benefit Researchers. American Journal of Bioethics, 2020, 20, 90-91.	0.5	4

#	Article	IF	Citations
37	Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations. American Journal of Bioethics, 2020, 20, 102-103.	0.5	4
38	Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?. American Journal of Bioethics, 2020, 20, 111-113.	0.5	4
39	Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk. American Journal of Bioethics, 2020, 20, 106-108.	0.5	4
40	Conjoined Consent: Informed Consent When Donor and Recipient Are Both Research Participants. American Journal of Bioethics, 2021, 21, 106-107.	0.5	4
41	Informed Consent Conversations: Neither the Beginning nor the End. American Journal of Bioethics, 2021, 21, 76-78.	0.5	4
42	Can Parents Refuse a Potentially Lifesaving Transplant for Severe Combined Immunodeficiency?. Pediatrics, 2016, 138, .	1.0	3
43	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. International Journal for Quality in Health Care, 2019, 31, 633-638.	0.9	3
44	The Need for Improved Access to Mental Health Services for Youth With Medically Unexplained Symptoms. American Journal of Bioethics, 2018, 18, 29-31.	0.5	3
45	Should Research Participants Be Notified About Results of Currently Unknown but Potential Significance?. American Journal of Bioethics, 2019, 19, 73-74.	0.5	3
46	Germline Gene Editing for Sickle Cell Disease. American Journal of Bioethics, 2020, 20, 46-49.	0.5	3
47	Click Here to Complete This Survey: Online Research, Adolescents, and Parental Consent. American Journal of Bioethics, 2020, 20, 82-83.	0.5	3
48	Supporting Investigators in Challenging Cases: Unease in the Face of an Ethically Appropriate Action. American Journal of Bioethics, 2021, 21, 98-99.	0.5	3
49	When Professional Meets Personal: How Should Research Staff Advertise on Social Media for Research Opportunities?. American Journal of Bioethics, 2021, 21, 38-39.	0.5	3
50	Pediatric Palliative Oncology Patients: Demographics, Treatment and End-of-Life Experiences of a Vulnerable and Understudied Population (TH340D). Journal of Pain and Symptom Management, 2018, 55, 580-581.	0.6	2
51	Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research. American Journal of Bioethics, 2020, 20, 8-10.	0.5	2
52	Opioid Management in the Dying Child With Addiction. Pediatrics, 2021, 147, e2020046219.	1.0	2
53	Minimally Conscious Assumptions and Dangerous Decision-Making Inferences. AJOB Neuroscience, 2013, 4, 61-63.	0.6	1
54	Allocation of Drugs in Short Supply. AMA Journal of Ethics, 2013, 15, 645-648.	0.4	1

#	Article	IF	CITATIONS
55	International Child Health Competencies. JAMA Pediatrics, 2015, 169, 621.	3.3	1
56	Navigating Nondisclosure Requests in Pediatrics. JAMA Pediatrics, 2017, 171, 1044.	3.3	1
57	Integrating Mental Health Care for Medically Complex Children. Pediatrics, 2020, 146, .	1.0	1
58	Supporting Community-Academic Research Partnerships: Reflections from the Ground. American Journal of Bioethics, 2021, 21, 44-45.	0.5	1
59	The Work of ASBH's Clinical Ethics Consultation Affairs Committee: Development Processes Behind Our Educational Materials. Journal of Clinical Ethics, 2018, 29, 150-7.	0.1	1
60	Enrolling Adolescents with Rare Disease for Early Phase Clinical Trials While Under the Care of Child Protection Services: Balancing Protection and Access. American Journal of Bioethics, 2022, 22, 81-82.	0.5	1
61	Time for a Reboot: Multimodal approaches to improving informed consent communication in pediatric oncology. Pediatric Blood and Cancer, 2022, 69, .	0.8	1
62	Ogilvie Syndrome in a Child With Incurable Malignancy (779). Journal of Pain and Symptom Management, 2012, 43, 467-468.	0.6	0
63	Response to the Letter to the Editor from Bleyer. Journal of Adolescent and Young Adult Oncology, 2015, 4, 93-93.	0.7	0
64	What Are the Limits of Parental Authority? Pediatric Bioethics and the Law (SA531). Journal of Pain and Symptom Management, 2016, 51, 401.	0.6	0
65	"l've Got This Difficult Case…―Ethics Facilitation and Documentation in Pediatrics (P15). Journal of Pain and Symptom Management, 2016, 51, 312-313.	0.6	0
66	Loss and Bereavement in Adolescent and Young Adult Oncology Patients (S740). Journal of Pain and Symptom Management, 2016, 51, 428-429.	0.6	0
67	When to Say When: Helping the Team and Family Recognize when Death is Inevitable After Pediatric Bone Marrow Transplant (TH356). Journal of Pain and Symptom Management, 2016, 51, 338.	0.6	0
68	An Extravagant Gift From a Grateful Patient. Pediatrics, 2018, 141, .	1.0	0
69	Ethical Considerations for Unblinding a Participant's Assignment to Interpret a Resolved Adverse Event. American Journal of Bioethics, 2018, 18, 66-67.	0.5	0
70	Autologous Hematopoietic Cell Transplantation without Transfusion in a Teenage Jehovah's Witness: A Case Report from a Pediatric Transplant Center. Biology of Blood and Marrow Transplantation, 2020, 26, S137.	2.0	0
71	Reducing Time to Discharge after Chemotherapy by Standardizing Workflow and Providing Outpatient Intravenous Hydration. Pediatric Quality & Safety, 2021, 6, e415.	0.4	0
72	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer., 2021 ,,.		0